Pay in 4 interest-free payments of $6.00 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
Early detection of any changes can help in adjusting the treatment plan promptly
Following GLP-1 deprescription, patients weight did not significantly increase at 6 or 12 months post deprescription, compared to many well-known drug trials (in red) where patients regain up to two thirds of weight loss after discontinuing the drug
The drug's off-label use for weight loss was noticed by providers and patients almost immediately, and Novo Nordisk responded by developing Wegovy, which also featured the same semaglutide molecule, just at a higher dose
Its such an insidious thing
Mounjaro ~22.5% average body weight loss Significant weight reduction Improves blood sugar levels Clinically proven weight loss Wegovy ~16.9% average body weight loss Boosts metabolic & cardiovascular health Proven, long-established safety profile Weekly injection, easy to use
US$ 28.02
US$ 25.87
US$ 20.08
US$ 28.33
US$ 25.49
